- Select a language for the TTS:
- UK English Female
- UK English Male
- US English Female
- US English Male
- Australian Female
- Australian Male
- Language selected: (auto detect) - EN
Play all audios:
Tome Biosciences has debuted with $213 million to bring their genome-editing platform to the clinic. The technology can insert large DNA sequences into the genome in any position to correct
genes in vivo. The tool, dubbed PASTE — programmable addition via site-specific targeting elements — was developed by Tome co-founders Omar Abudayyeh and Jonathan Gootenberg from the
Massachusetts Institute of Technology. Investors include Andreessen Horowitz, Arch Venture Partners, Polaris and Fujifilm.
PASTE uses a CRISPR–Cas9 nickase fused with two other enzymes: a reverse transcriptase and a serine integrase. The guide RNA-directed reverse transcriptase creates landing sites for the
serine integrase, which inserts large sequences of DNA. Tome has shown that its tool can insert sequences of ~36 kb in various dividing and non-dividing cell types. And, unlike other editing